While experimental desensitization strategies are available in research settings, people with food allergies must avoid known allergens and are advised to carry injectable epinephrine to prevent potentially life-threatening allergic reactions caused by accidental exposures. To help alleviate this risk, a new study to evaluate an experimental treatment for food allergy launched today.
Kids With Food Allergies is sharing these press releases from Aimmune Therapeutics and DBV Technologies to bring you the latest research news quickly. [PRESS RELEASE] Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy BRISBANE, Calif.– (BUSINESS WIRE) – Feb. 20, 2018 – Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced...
The future of food allergy: developing new treatments by Michael H. Land, MD FAAAAI I'm the father of a food allergic child. If you're reading this, I am guessing you or someone close to you has a food allergy. The minute you found out...
This gives me hope that my child will eventually be allergy free and his life will not be in danger from a simple item of food! Thank you so much for this great article in layman terms so that we parents can understand it!
Hi Michael, Very interesting for us to read as I have more than one grandchild with food allergies! Congratulations on all your accomplishments and studies. Love from us all, your old Oxford neighbour!
Welcome Jessica & Sandra! We are glad you found KFA. We hope you will join us on our Support Forums. We have several forums that may be of interest. Main Forum Babies, Toddlers & Preschoolers We even have a new forum for saving money! http://community.kidswithfooda...s-for-food-allergies We have a fantastic Food & Cooking forum Don't forget to check out our recipe section! Come join us! .
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent® (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE). The trial met both of its co-primary endpoints, as well as all key secondary endpoints. Dupixent is the first and only biologic to show positive and clinically-meaningful results in this population as part of a Phase 3 trial.
COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders (CNPs), today announced the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for evaluation of COUR's CNP-201 in a proof-of-concept (Phase 1 / 2) study in people who are allergic to peanuts.
When you block a person, they can no longer invite you to a private message or post to your profile wall. Replies and comments they make will be collapsed/hidden by default. Finally, you'll never receive email notifications about content they create or likes they designate for your content.
Note: if you proceed, you will no longer be following .